Latest From Vivus Inc.
Kowa Pharmaceuticals' patient testimonials implying switch from statins to Livalo will reduce drug side effects are misleading, untitled letter says.
‘Untitled’ letter is FDA's third in the past eighteen months to target promotions for women’s health products. In the case of advertisement for CooperSurgical's copper-containing intrauterine device, which is regulated as a drug, the agency took issue with distracting visuals and reliance on superimposed text.
Claims that Vivus' obesity drug helps patients lose weight faster than diet and exercise alone are false and misleading because the clinical studies were not designed to evaluate the rate of weight loss over time, Office of Prescription Drug Promotion says in untitled letter; Vivus says it is finalizing revisions to its promotions.
Fixed-dose combination of phentermine and topiramate is FDA-approved for chronic, long-term use, but the average duration in the real world is only about 2.1 months, which is reassuring for Qsymia’s cardiovascular safety, according to a new retrospective claims study.
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
- Vivus Inc.
- Senior Management
Thomas B King, Interim CEO
Mark K Oki, CFO & Chief Accounting Officer
Deborah W Larsen, PhD, Chief Commercial Officer
John L Slebir, SVP, Bus. Dev. & General Counsel
Santosh T Varghese, MD, CMO
- Contact Info
Phone: (650) 934-5200
900 E. Hamilton Ave
Campbell, CA 95008
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.